Abstract:
PURPOSE: A composition containing L-serine for preventing and treating fatty liver diseases is provided to suppress transcription of SREBP-1(sterol regulatory element-binding protein-1) and accumulation of neutral fat in a liver tissue. CONSTITUTION: A pharmaceutical composition for preventing and treating fatty liver diseases contains L-serine as an active ingredient. The L-serine contains the compound itself or pharmaceutically acceptable salt and solvate. The fatty liver diseases include alcoholic fatty liver, non-alcoholic fatty liver, diabetic fatty liver, or steatohepatitis. A health food for preventing and treating fatty liver diseases contain the L-serine as an active ingredient. The health food includes beverage, gum, vitamin complex, or supplementary food.
Abstract:
Provided is a composition for prevention or treatment of fatty liver diseases by employing honokiol capable of increasing activity of PPAR-alpha which controls synthesis of an enzyme related to oxidation of fat. A composition for prevention or treatment of fatty liver diseases comprises honokiol represented by the formula 1 as an active ingredient. The honokiol is separated from a silver magnolia and refined. The Honokiol suppresses activity of SREBP-1 which controls synthesis of an enzyme related to biosynthesis of fat. A method for separating the Honokiol consists of a step of dispersing a 70% ethanol extract solution of dried stems of the silver magnolia in water.
Abstract:
본 발명은 후박( Magnolia cortex) 추출물, 이의 분획물 또는 추출정제물을 유효성분으로 함유하는 지방간 질환 예방 및 치료용 조성물에 관한 것으로서, 더욱 상세하게는 물, 알코올 또는 이들의 혼합물을 용매로 하여 추출되는 후박 추출물, 이의 분획물 및 추출정제물은 간 속의 S-아데노실-L-메치오닌(S-adenosyl-L-methionine) 및 글루타치온(Gluthathione)의 함량을 증가시켜 간 손상을 억제하고, 간 조직 내에서의 중성지방 축적 억제 효과를 나타냄을 확인함으로써 지방간 질환 예방 및 치료용 조성물로 유용하게 이용될 수 있다.
Abstract:
본 발명은 호노키올을 유효성분으로 함유하는 지방간 질환의 예방 및 치료용 조성물에 관한 것으로, 본 발명에 따른 호노키올은 알코올에 의해 저해된 지방산 분해 조절 전사인자(PPAR-α)를 전사 활성화하고 알코올에 의해 활성화된 지방산 생합성 조절전사인자(SREBP-1)를 전사 억제함으로서 간 조직 내의 중성지방 축적을 억제하여 지방간 질환의 예방 및 치료용 조성물 및 건강기능식품으로 유용하게 이용될 수 있다. 호노키올, 후박, 지방간, 중성지방
Abstract:
A pharmaceutical composition containing magnolia cortex extracts is provided to increase the amount of S-adenosyl-L-methionine and Gluthathione in order to prevent triglycerides storage in a liver. A pharmaceutical composition containing magnolia cortex extracts comprises Magnolia cortex extracts obtained by using a solvent such as water, alcohols, or its mixture. The Magnolia cortex is selected from the group consisting of Magnolia obovata Thunberg, Magnolia officinale Rehder et Wils, and Machilus thunbergii Sieb.et Zucc. The alcohol is a C1-C4 low alcohol. The pharmaceutical composition additionally includes Magnolia cortex extracts obtained by using ethylacetate.